This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BioWorld's Top 10 Most Impactful Biopharmaceutical Stories Of 2012

ATLANTA, Dec. 27, 2012 /PRNewswire-USNewswire/ -- Biotechnology played a pivotal role in the development of more targeted drugs in 2012 as the science continues to elucidate the molecular mechanisms of diseases. The volatile biopharmaceutical industry ‑ historically comprised of venture-backed start-ups ‑ produced some whopping news in 2012, from the first new obesity drug in 13 years to a heated race to develop the first all-oral, side-effect-free treatment for hepatitis C. Nothing, however, was bigger than the arrival of the pharmaceutical industry at the long-dreaded patent cliff.


As blockbuster drugs began going off patent in droves, big pharmas saw sales swoon, creating potential opportunities for nimble biotechs – particularly in technologies such as therapeutic vaccines, stem cells and tissue replacement. Erosion from generics will erase some $148 billion from pharma industry revenues by 2018.

"BioWorld's editorial team voted on the 10 most poignant stories that emerged in 2012, and big pharma's patent cliff was undeniably No. 1," said Lynn Yoffee, BioWorld's executive editor. "As the stalwart pharmaceutical giants are stumbling to replace lost revenues and replenish development pipelines, they are either turning to partner with biopharmaceutical firms or building their own biotech divisions. Either way, it's a nod to the increased reliance on the science of biotechnology as a primary driver in the development of the most effective human therapeutics."

Read about BioWorld's Top 10 at

The other nine stories of 2012 include:2. The All-Oral HCV Race3. New Obesity Drugs Pass FDA Muster4. Two Firsts: Biologic Blockbuster and Biosimilar MAb5. The Rocky Fundraising Road Continued6. JOBS Act + FDASIA Pass Despite U.S. Political Squabbles7. Genomics Finally Arrives (With a Real Purpose)8. The First Gene Therapy is Approved9. Through the Thicket of Alzheimer's Failures10. A Nobel Prize for Regenerative Medicine Breakthrough

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs